



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Earl Ray Tomblin
Governor

Bureau for Medical Services
Pharmacy Services
350 Capitol Street – Room 251
Charleston, West Virginia 25301-3706
Telephone: (304) 558-1700 Fax: (304) 558-1542

Karen L. Bowling
Cabinet Secretary

Pharmaceutical and Therapeutics Committee
April 23, 2014

Location: Diamond, Rooms B10 and B11
Time: 2:00 PM – 5:00 PM
Charleston, WV 25301
(304) 558-1700

MINUTES

Members Present:

Jeffrey V. Ashley, M.D.
David Avery, M.D.
Elizabeth Baldwin, RN, MSN, PNP, APRN-BC
Scott Brown, R.Ph.
Michael Grome, PA-C
Bradley Henry, M.D.
Tom Kines, R.Ph.
Steven R. Matulis, M.D, Chairman
Harriet Nottingham, R.Ph.
Robert Stanton, Pharm.D., Vice Chairman

Members Not Present:

Rodney L. Fink, D.O.
Amelia McPeak, D.O.

DHHR/BMS Staff Present:

Vicki Cunningham, R.Ph., Pharmacy Director
Brian Thompson, MS, Pharm.D., DUR Coordinator
William Hopkins, Pharmacy Operations Manager
Gail Goodnight, R.Ph., Drug Rebate Program
Director
Richard D. Sorvig, Administrative Assistant

**Contract Staff/Magellan Medicaid
Administration (MMA) Staff Present:**

Nina Bandali, Pharm.D.
Giovannino Perri, M.D.

Other Contract Staff/State Staff Present:

Eric Sears, R.Ph., Molina Medicaid Solutions
Steve Small, R.Ph., MS, Director, Rational Drug
Therapy Program

I. Call to Order

Dr. Steven Matulis, Chairman, called the meeting to order at 2:06PM.

II. Welcome and Introductions

All parties seated at the table and on the phone introduced themselves.

III. Housekeeping Items/Updates

A. Approval of the January 29, 2014 Minutes

Dr. Matulis asked for approval of the minutes from the January 29, 2014 P&T meeting. A motion was made and seconded; the motion carried to approve the minutes as submitted.

B. PDL Compliance/Generic Percent Report Updates

Dr. Nina Bandali reported the overall PDL compliance for Q4 2013 was 97.0% and the generic utilization rate for Q4 2013 was 79.3%.

IV. Public Comments

Ms. Cunningham explained the public comment process, including the time limit of three minutes per product for each speaker. The following people spoke:

Ali Toumadj, Gilead representative, spoke in favor of Sovaldi.

Stephen A. Lewis, MD, spoke in favor of Effient.

V. Executive session

The motion was made and seconded to adjourn to executive session for confidential pricing discussion. A vote was taken and the motion was approved at 2:15PM. The meeting resumed at 3:12PM.

VI. Old Business

None

VII. New Business

A. New Generics

Dr. Bandali stated that the following generics are non-preferred:

duloxetine (generic for Cymbalta)

telmisartan/amlodipine (generic for Twynsta)

telmisartan (generic for Micardis)

tolterodine ER (generic for Detrol LA)

lamivudine HBV (generic for Epivir HBV)

ribavirin dose pack (generic for Ribapak)

mycophenolic acid (generic for Myfortic)

sirolimus (generic for Rapamune)

morphine ER capsule (generic for Avinza)

doxercalciferol injection (generic for Hectoral injection)

B. Re-Review

1. Bethkis

It was stressed that the Committee did not want to set a precedent to re-review products; although, the Bureau has the prerogative to do such that it is in the State's best interest. The rationale for the re-review of Bethkis was questioned. Dr. Bandali responded the decision to re-review Bethkis was based on financial reasons. MMA recommended that Bethkis be moved to preferred. The motion to approve the recommendation as presented was made and seconded. A vote was taken and the motion was approved.

ANTIBIOTICS, INHALED

BETHKIS (tobramycin)

TOBI (tobramycin)

CAYSTON (aztreonam)

TOBI PODHALER
tobramycin

2. Effient

The rationale to re-review Effient was questioned. Dr. Bandali responded that it was based on financial reasons and utilization data. MMA recommended that Effient be moved to preferred. The motion to approve the recommendation as presented was made and seconded. A vote was taken and the motion was approved.

PLATELET AGGREGATION INHIBITORS

AGGRENOX (dipyridamole/ASA)

BRILINTA (ticagrelor)

clopidogrel

EFFIENT (prasugrel)^{CL*}

dipyridamole

PERSANTINE (dipyridamole)

PLAVIX (clopidogrel)

TICLID (ticlopidine)

Ticlopidine

C. New Drug Reviews

The Committee expressed their disappointment in the manufacturer and that they were appalled at the outrageous pricing of Sovaldi at \$1000 per tablet. MMA recommended that Sovaldi be nonpreferred. The motion to table the decision on Sovaldi until the August meeting was made and seconded. A vote was taken and the motion was approved with one opposed.

1. Sovaldi

HEPATITIS C TREATMENTS^{CL}

INCIVEK (telaprevir)*

PEGASYS (pegylated interferon)

PEG-INTRON (pegylated interferon)

ribavirin

VICTRELIS (boceprevir)*

COPEGUS (ribavirin)

INFERGEN (consensus interferon)

REBETOL (ribavirin)

RIBAPAK (ribavirin)

RIBASPHERE 400mg, 600mg (ribavirin)

ribavirin dose pack

The Bureau is considering prior authorization criteria for Sovaldi. The criteria will be presented to the DUR Board at the next meeting on May 21, 2014.

VIII. Next Meeting

The next P&T meeting is scheduled for August 27, 2014 at 2PM in the Bureau for Medical Services' offices, Diamond Building, 350 Capitol Street, Charleston, WV.

IX. Other Business

None

X. Adjournment

The meeting was adjourned at 3:22PM.